Literature DB >> 25604559

Building the case for novel clinical trials in pulmonary arterial hypertension.

John J Ryan1, Jonathan D Rich2, Bradley A Maron2.   

Abstract

Entities:  

Keywords:  controlled trials, randomized; heart failure; heart failure, right-sided; hypertension, pulmonary; idiopathic pulmonary arterial hypertension; pulmonary vascular resistance

Mesh：

Substances：

Year:  2015        PMID： 25604559      PMCID： PMC4304412          DOI： 10.1161/CIRCOUTCOMES.114.001319

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN： 1941-7713


× No keyword cloud information.
  57 in total

1.  Safety and efficacy of exercise training in various forms of pulmonary hypertension.

Authors:  Ekkehard Grünig; Mona Lichtblau; Nicola Ehlken; Hossein A Ghofrani; Frank Reichenberger; Gerd Staehler; Michael Halank; Christine Fischer; Hans-Jürgen Seyfarth; Hans Klose; Andreas Meyer; Stephan Sorichter; Heinrike Wilkens; Stephan Rosenkranz; Christian Opitz; Hanno Leuchte; Gabriele Karger; Rudolf Speich; Christian Nagel
Journal:  Eur Respir J       Date:  2012-02-09       Impact factor: 16.671

2.  Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension.

Authors:  Yoshihiro Fukumoto; Norikazu Yamada; Hiromi Matsubara; Minori Mizoguchi; Kazuaki Uchino; Atsushi Yao; Yasuki Kihara; Mitsuhiro Kawano; Hiroshi Watanabe; Yutaka Takeda; Takeshi Adachi; Shinobu Osanai; Nobuhiro Tanabe; Teruo Inoue; Akihiro Kubo; Yuri Ota; Koichiro Fukuda; Takeshi Nakano; Hiroaki Shimokawa
Journal:  Circ J       Date:  2013-08-03       Impact factor: 2.993

3.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

4.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

5.  Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.

Authors:  Gianluigi Savarese; Stefania Paolillo; Pierluigi Costanzo; Carmen D'Amore; Milena Cecere; Teresa Losco; Francesca Musella; Paola Gargiulo; Caterina Marciano; Pasquale Perrone-Filardi
Journal:  J Am Coll Cardiol       Date:  2012-09-25       Impact factor: 24.094

6.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

Authors:  J H Newman; L Wheeler; K B Lane; E Loyd; R Gaddipati; J A Phillips; J E Loyd
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

7.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

Review 9.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Florent Soubrier; Wendy K Chung; Rajiv Machado; Ekkehard Grünig; Micheala Aldred; Mark Geraci; James E Loyd; C Gregory Elliott; Richard C Trembath; John H Newman; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

10.  Role for miR-204 in human pulmonary arterial hypertension.

Authors:  Audrey Courboulin; Roxane Paulin; Nellie J Giguère; Nehmé Saksouk; Tanya Perreault; Jolyane Meloche; Eric R Paquet; Sabrina Biardel; Steeve Provencher; Jacques Côté; Martin J Simard; Sébastien Bonnet
Journal:  J Exp Med       Date:  2011-02-14       Impact factor: 14.307
View more
  8 in total

Review 1.  Update in Pulmonary Vascular Disease 2015.

Authors:  Bradley A Maron; Mark T Gladwin; Marc A Simon
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

Review 2.  The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials (2015 Grover Conference Series).

Authors:  Jessica H Huston; John J Ryan
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

3.  Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension.

Authors:  Meghan M Cirulis; John J Ryan
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

4.  Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.

Authors:  Azadeh Issapour; Benjamin Frank; Sarah Crook; Michelle D Hite; Michelle L Dorn; Erika B Rosenzweig; D Dunbar Ivy; Usha S Krishnan
Journal:  Pediatr Pulmonol       Date:  2022-01-03

5.  Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Authors:  John H Newman; Stuart Rich; Steven H Abman; John H Alexander; John Barnard; Gerald J Beck; Raymond L Benza; Todd M Bull; Stephen Y Chan; Hyung J Chun; Declan Doogan; Jocelyn Dupuis; Serpil C Erzurum; Robert P Frantz; Mark Geraci; Hunter Gillies; Mark Gladwin; Michael P Gray; Anna R Hemnes; Roy S Herbst; Adrian F Hernandez; Nicholas S Hill; Evelyn M Horn; Kendall Hunter; Zhi-Cheng Jing; Roger Johns; Sanjay Kaul; Steven M Kawut; Tim Lahm; Jane A Leopold; Greg D Lewis; Stephen C Mathai; Vallerie V McLaughlin; Evangelos D Michelakis; Steven D Nathan; William Nichols; Grier Page; Marlene Rabinovitch; Jonathan Rich; Franz Rischard; Sharon Rounds; Sanjiv J Shah; Victor F Tapson; Naomi Lowy; Norman Stockbridge; Gail Weinmann; Lei Xiao
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

6.  Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges.

Authors:  Annie-Christine Lajoie; Sebastien Bonnet; Steeve Provencher
Journal:  Pulm Circ       Date:  2017-05-30       Impact factor: 3.017

7.  Clinical trial design in phase 2 and 3 trials for pulmonary hypertension.

Authors:  Sylvia Nikkho; Peter Fernandes; R James White; Chunqin Cq Deng; Harrison W Farber; Paul A Corris
Journal:  Pulm Circ       Date:  2020-07-20       Impact factor: 3.017

8.  Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.

Authors:  Jacqueline V Scott; Christine E Garnett; Manreet K Kanwar; Norman L Stockbridge; Raymond L Benza
Journal:  Am J Respir Crit Care Med       Date:  2021-03-15       Impact factor: 21.405
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.